+

WO2002044160A1 - Medicaments pour lutter contre la pancreatite et produits medicinaux pour prevenir et traiter l'oesophagite peptique - Google Patents

Medicaments pour lutter contre la pancreatite et produits medicinaux pour prevenir et traiter l'oesophagite peptique Download PDF

Info

Publication number
WO2002044160A1
WO2002044160A1 PCT/JP2001/010457 JP0110457W WO0244160A1 WO 2002044160 A1 WO2002044160 A1 WO 2002044160A1 JP 0110457 W JP0110457 W JP 0110457W WO 0244160 A1 WO0244160 A1 WO 0244160A1
Authority
WO
WIPO (PCT)
Prior art keywords
remedies
pancreatitis
medicines
therapy
prevention
Prior art date
Application number
PCT/JP2001/010457
Other languages
English (en)
Japanese (ja)
Inventor
Kazumi Ogata
Kazuhiko Ito
Shinya Ogino
Takahiro Sakaue
Masahito Iemura
Original Assignee
Senju Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co., Ltd. filed Critical Senju Pharmaceutical Co., Ltd.
Priority to AU2002218505A priority Critical patent/AU2002218505A1/en
Publication of WO2002044160A1 publication Critical patent/WO2002044160A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des médicaments pour lutter contre la pancréatite et des produits médicinaux pour prévenir et traiter l'oesophagite peptique, contenant comme principe actif, les composés de formule générale (I) ou leurs sels pharmaceutiquement tolérables. Dans la formule (I), R1 et R2 désignent à la fois hydrogène, ou autrement, R1 et R2 sont combinés pour former CH=CH-CH=CH ; R3 et R4 désignent indépendamment l'un de l'autre hydrogène, alkyle inférieur, alcoxy inférieur, ou halogéno ; et Q représente soit une liaison directe par liaison entre le composé cyclique pipérazone et le composé cyclique aromatique, ou A-(CH2)m- (où A désigne oxygène, soufre, ou CH2 ; et m est un nombre entier compris entre 1 et 10).
PCT/JP2001/010457 2000-11-30 2001-11-29 Medicaments pour lutter contre la pancreatite et produits medicinaux pour prevenir et traiter l'oesophagite peptique WO2002044160A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002218505A AU2002218505A1 (en) 2000-11-30 2001-11-29 Pancreatitis remedies and medicines for prevention and therapy of reflux esophagitis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2000365044 2000-11-30
JP2000-365044 2000-11-30
JP2001-091449 2001-03-27
JP2001091449 2001-03-27

Publications (1)

Publication Number Publication Date
WO2002044160A1 true WO2002044160A1 (fr) 2002-06-06

Family

ID=26604947

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/010457 WO2002044160A1 (fr) 2000-11-30 2001-11-29 Medicaments pour lutter contre la pancreatite et produits medicinaux pour prevenir et traiter l'oesophagite peptique

Country Status (2)

Country Link
AU (1) AU2002218505A1 (fr)
WO (1) WO2002044160A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0455510A2 (fr) * 1990-05-04 1991-11-06 Eli Lilly And Company Utilisation de composés à activité agoniste du récepteur 5-HT1A pour inhiber la sécrétion d'acide gastrique
EP0870502A2 (fr) * 1997-04-10 1998-10-14 Kyowa Hakko Kogyo Co., Ltd. Utilisation d'inhibiteurs de l'assimilation d'adénosine pour la fabrication d'un médicament pour le traitement de la pancréatite
JP2000229998A (ja) * 1998-12-08 2000-08-22 Fujisawa Pharmaceut Co Ltd 新規化合物
WO2001034569A1 (fr) * 1999-11-11 2001-05-17 Senju Pharmaceutical Co., Ltd. Medicaments contre la pancreatite
WO2001066551A2 (fr) * 2000-03-07 2001-09-13 Ranbaxy Laboratories Limited Composes azole comme agents therapeutiques pour traiter des infections mycosiques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0455510A2 (fr) * 1990-05-04 1991-11-06 Eli Lilly And Company Utilisation de composés à activité agoniste du récepteur 5-HT1A pour inhiber la sécrétion d'acide gastrique
EP0870502A2 (fr) * 1997-04-10 1998-10-14 Kyowa Hakko Kogyo Co., Ltd. Utilisation d'inhibiteurs de l'assimilation d'adénosine pour la fabrication d'un médicament pour le traitement de la pancréatite
JP2000229998A (ja) * 1998-12-08 2000-08-22 Fujisawa Pharmaceut Co Ltd 新規化合物
WO2001034569A1 (fr) * 1999-11-11 2001-05-17 Senju Pharmaceutical Co., Ltd. Medicaments contre la pancreatite
WO2001066551A2 (fr) * 2000-03-07 2001-09-13 Ranbaxy Laboratories Limited Composes azole comme agents therapeutiques pour traiter des infections mycosiques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AGARWAL SHIV K. ET AL.: "Synthesis and pharmacological activities of 1-(2,4-disubstituted phenoxy)-3-(N1-(N4-arylpiperazinyl)) propanes and 1-(4-chlorobenzoyl)-3-substituted 6-methoxy-2-(4-(3-N1-(N4-phenylpiperazinyl)propoxy)phenyl)indoles", INDIAN J. CHEMICAL, SECT. B, vol. 30B, no. 4, 1991, pages 413 - 416, XP002909067 *
SAXENA ANIL K. ET AL.: "Synthesis and QSAR studies on hypotensive N-(3-aryl(thio/sulfono)propyl) piperazines/piperidines", INDIAN J. CHEMICAL, SECT. B, vol. 32B, no. 12, 1993, pages 1249 - 1257, XP002909066 *
TOSHIKAZU SEKIGUCHI: "Esophageal affection, reflux esophagitis/esophageal ulcer", MEDICINA, vol. 31, no. 1, 1994, pages 6 - 10, XP002909065 *

Also Published As

Publication number Publication date
AU2002218505A1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
EP1550662A4 (fr) Nouveau compose d'adenine et son application
NO20093253L (no) Forbindelser, farmasoytiske formuleringer og anvendelse av forbindelsene til fremstilling av legemiddel
EP1642880A4 (fr) Inhibiteur de proteines de la famille hsp90
EP1236719A4 (fr) Nouveaux composes heterocycliques et sels de ces derniers, utilisations de ces composes en medecine
YU65902A (sh) Farmaceutske smeše koje sadrže derivate 3-aminoazetidina, novi derivati i njihovo spravljanje
WO1998035951A3 (fr) Nouveaux derives d'aminopiperazine
EP0970954A4 (fr) Derives du 3-piperidyl-4-oxoquinazoline et compositions medicinales les contenant
RS50140B (sr) Postupak za dobijanje perkihinina i njegova upotreba
CA2360360A1 (fr) Piperidylbenzamides , compositions comportant ces composes et leur utilisation
ATE218345T1 (de) Arzneimittel gegen spinocerebellare degeneration
MY139461A (en) Condensed furan compounds
WO2003024953A1 (fr) Derive de propanolamine a noyau 1,4-benzodioxane
AU2267495A (en) Benzamide derivatives as vasopressin antagonists
EP1295608A4 (fr) Agent therapeutique contre l'anxiete nevrotique ou la depression et derive de piperazine
NZ514542A (en) Vasopressin antagonists for the treatment of pulmonary hypertension
WO2002000638A3 (fr) Nouveaux phthalides substitues, leur procede de preparation et compositions pharmaceutiques les contenant
AU2001269540A1 (en) Serotonin reuptake inhibitors
WO2003031414A1 (fr) Nouveau compose heterocyclique et agent anti-inflammatoire
EP1256581A4 (fr) Agents preventifs et therapeutiques de la regurgitation gastrique ou oesophagienne
AU2002214336A1 (en) Pharmaceutical preparations containing a dibenzocyclooctane lignan derivative for prevention and treatment of neurodegenerative disease
EP1537879A4 (fr) Medicaments preventifs et/ou therapeutiques contre l'asthme
WO2002044160A1 (fr) Medicaments pour lutter contre la pancreatite et produits medicinaux pour prevenir et traiter l'oesophagite peptique
EP1142883A4 (fr) Nouveaux composes heterocycliques et compositions de medicaments les renfermant
EP1004308A4 (fr) Agents prophylactiques ou remedes contre les troubles renaux d'origine medicamenteuse
NZ527230A (en) Crystal form of a cyclic depsipeptide having improved activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载